| Project/Area Number |
24659383
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Circulatory organs internal medicine
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
SUZUKI Toru 東京大学, 医学部附属病院, 准教授 (90359620)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
AIZAWA Kenichi 東京大学, 医学部附属病院, 特任助教 (70436484)
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 循環器・高血圧 / 蛋白質 / プロテオーム / ストレス / 動脈硬化 |
|---|
| Research Abstract |
It is revealed that endocrine control participates in the condition of a patient of the cardiovascular disease and in late years attracts attention as the field of cardiovascular endocrinology. We pursued the generation mechanism of the fragment which selective bioactive peptide caught the processing to heart seen at the time of arteriosclerosis. We examined whether human recombinant performed a process of this bioactive peptide using a mass spectrometer. In addition, we performed examination whether or not the activity of this enzyme was seen in blood and examined correlation with the condition of a patient. As a result, in the coronary restenotic condition of a patient, we made clear that a piece of the specific bioactive peptide decreased. It is expected future arteriosclerotic new diagnostic agent, that, besides, it is a beginning of the development of the antiarteriosclerotic drug.
|
